Exclusive Hyper-fractionated Radiotherapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the two French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups.
Fiche publication
Date publication
août 2020
Journal
International journal of radiation oncology, biology, physics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie, Pr TRUC Gilles, Dr VIGNERON Céline
Tous les auteurs :
Carrie C, Kieffer V, Figarella-Branger D, Masliah-Planchon J, Bolle S, Bernier V, Laprie A, Supiot S, Leseur J, Habrand JL, Alapetite C, Kerr C, Dufour C, Claude L, Chapet S, Huchet A, Bondiau PY, Escande A, Truc G, Nguyen TD, Pasteuris C, Vigneron C, Muracciole X, Bourdeaut F, Appay R, Dubray B, Colin C, Ferlay C, Dussart S, Chabaud S, Padovani L,
Lien Pubmed
Résumé
Medulloblastoma has recently been characterized as a heterogeneous disease with four distinct molecular subgroups: wingless (WNT), sonic hedgehog (SHH), group 3 and group 4, with new definition of risk stratification. We report progression-free survival, overall survival, and long-term cognitive effects in children with standard-risk medulloblastoma exclusively treated with hyper-fractionated radiotherapy (HFRT), reduced boost volume, online quality control, and we explore the prognostic value of biological characteristics in this chemotherapy-naive population.
Mots clés
Medulloblastoma, craniospinal irradiation, cytogenetic prognostication, hyperfractionated radiotherapy, pediatric radiotherapy, prognosis, quality assurance, risk-assessment
Référence
Int. J. Radiat. Oncol. Biol. Phys.. 2020 Aug 5;: